METHOD FOR SOLUBILIZING POORLY WATER-SOLUBLE DIETARY SUPPLEMENTS AND PHARMACEUTICALLY ACTIVE AGENTS

Abstract

The present invention relates to a method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents, to the solubilisate produced by this method and respective uses as a dietary supplement or pharmaceutical dosage form. A phosphatidylcholine-based solubilization method is disclosed.

Claims

1. A method for solubilizing a pharmaceutically active agent or a dietary supplement, comprising the following steps: (a) Providing at least one pharmaceutically active agent or dietary supplement in the overall range of 0.5% to 25% per weight at room temperature and a pressure of 0.2 bar to 1 bar; (b) Adding in any sequence the solubilization agents of at least one phosphatidylcholine in the overall range of 20% to 80% per weight, at least one medium-chained triglyceride in the overall range of 10% to 70% per weight, at least one lysophosphatidyleholine in the overall range of 1% to 15% per weight, at least one C.sub.2 to C.sub.4 alcohol in the overall range of 1% to 20% per weight, and at least one of glyceryl stearate and/or a saturated or unsaturated C.sub.14 to C.sub.20 fatty acid in the overall range of 0.5% to 10% per weight, respectively, wherein the relative weight percentages of all ingredients add up to 100% and all solubilization agents are independently from one another a food additive and/or a pharmaceutically acceptable excipient; (c) Cautiously heating the resulting mixture by continuously increasing the temperature with a continuous temperature increment of 0.5° C./min to 3° C./min over a period of 20 to 60 minutes; (d) Stopping the temperature increase in a temperature range of 30° C. to 125° C. as soon as a clear solution is reached; and (e) Letting the resulting solubilisate cool down to room temperature.

2. The method according to claim 1, wherein said at least one saturated or unsaturated C.sub.14 to C.sub.20 fatty acid is oleic acid.

3. The method according to claim 1, wherein said at least one C.sub.2 to C.sub.4 alcohol is ethanol.

4. The method according to claim 1, wherein additionally in step b) at least one antioxidant in the overall range of 0.01 to 10% per weight is added, said at least one antioxidant being a food additive and/or a pharmaceutically acceptable excipient.

5. The method according to claim 4, wherein said at least one antioxidant is ascorbyl palmitate and/or at least one tocopherol.

6. The method according to claim 1, wherein the resulting solubilisate is used to mask a bitter or unpleasant taste and/or odor of the pharmaceutically active agent or dietary supplement.

7. A solubilisate of at least one pharmaceutically active agent or dietary supplement, produced by a method as defined in claim 1, wherein the solubilisate comprises glyceryl stearate.

8. A solubilisate according to claim 7 for use to mask a bitter or unpleasant taste and/or odor of the pharmaceutically active agent or dietary supplement

9. Use of the solubilisate as defined in claim 7 in medicine.

10. The solubilisate according to claim 7, in which the solubilisate of the at least one dietary supplement and/or pharmaceutically active agent enhances the resorption and/or bioavailability of at least one of said dietary supplements or pharmaceutically active agents.

11. The solubilisate according to claim 7, in which the dietary supplement is selected from the group containing coenzyme Q.sub.10, green tea extract and piperine, or the pharmaceutically active agent is selected from the group containing hydrochlorothiazide, aciclovir and azithromycin.

12. A finished solution, wherein the solubilisate according to claim 7 is solved in an aqueous solution.

13. A pharmaceutical composition containing at least one pharmaceutically active agent formulated in a solubilisate as defined in claim 7 or in a finished aqueous solution as defined in claim 12 and at least one pharmaceutically acceptable excipient, respectively.

14. A pharmaceutical composition according to claim 13, wherein said at least one pharmaceutically acceptable excipient is selected from a group comprising carriers, binding agents, lubricants, glidants, disintegrants, colorants, buffers, preservatives, emulsifiers, permeation enhancers, antioxidants, diluents, pH-regulators, fatliquors, solvents, consistency enhancers, hydrotropes, sweeteners, acidifiers, thickening agents, antiadherents, fillers, flavors, sweeteners, opacifiers, flavoring substances and aromatic substances.

15. A pharmaceutical composition according to claim 13, wherein the at least one pharmaceutically active agent is a BCS Class 4 pharmaceutically active agent selected from a group consisting of acetaminophen, aciclovir, azathioprine, azithromycin, calcitriol, carisoprodol, cefdinir, cefixime, cefuroxime axetil, cephalexin, chlorothiazide, chlorthalidone, clarithromycin, cyclosporine, dapsone, dexamethasone, dronabinol, dutasteride, furosemide, glipizide, griseofulvin, hydrochlorothiazide, indinavir sulfate, isradipine, linezolid, loperamide, mebendazole, mercaptopurine, mesalamine, methylprednisolone, modafinil, nabumetone, nelfinavir mesylate, norelgestromin, nystatin, oxcarbazepine, oxycodone HCl, progesterone, pyrimethamine, ritonavir, spironolactone, sulfamethoxazole, trimethoprim and taladafil.

Description

EXAMPLES

[0175] In the ensuing examples the relative quantities of the solubilizing agents can be changed inside the margins indicated for each component in the method according to the invention. The addition of glyceryl oleate and tocopherol is optional.

[0176] The resulting solubilisate can be diluted with an aqueous solution in order to obtain a finished solution. The volume of the aqueous solution can vary according to the desired volume of the finished solution.

[0177] It is possible to upscale or downscale the indicated amounts according to the desired absolute amount of the agent to be solubilized in the solubilisate. The solubilisate can be portioned according to the desired final amount of the agent that shall be administered to a patient in need thereof or consumed by a dietary supplement user.

[0178] In general, the produced solubilisates produced according to the method of the invention had a specific gravity of 0.92-0.94.

[0179] Standard chemicals were purchased from Sigma-Aldrich, Darmstadt, Germany.

Example 1: Solubilization of Azithromycin

[0180] Azithromycin is a broad-spectrum antibiotic that is widely used against infections by some Gram-positive, some Gram-negative and many atypical bacteria. Azithromycin belongs to BCS Class 4 (low solubility—low permeability) pharmaceuticals.

[0181] Ca. 10 ml of a solubilisate of azithromycin were generated by the following procedure: 200 mg azithromycin (Sigma-Aldrich, Darmstadt, Germany) were provided. 3.4 g 1-pamitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC; Lipoid GmbH, Ludwigshafen, Germany), 5.5 ml MCT oil (Azelis, Moers, Germany), 320 mg L-alpha-lysophosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany), 300 μl ethanol, 110 μl oleic acid, 170 mg glyceryl stearate, 15 μl glyceryl oleate and 8 mg tocopherol were added under stirring for 5 min at room temperature (20±5° C.) and atmospheric pressure. Then the composition was cautiously heated under continued stirring, with an approximate temperature increment of 2° C./min. After ca. 8 min (ca. 36° C.) the composition started to become a clear solution. This solubilization process lasted for ca. 7 min more. Thus a solubilisate according to the invention was obtained after ca. 15 min at ca. 50° C. Then the heating and the stirring was stopped and the resulting solubilisate was allowed to cool down to room temperature. The solubilisate stayed clear and stable over min. 1 month.

[0182] Upon being diluted into an aqueous finished solution (2 ml solubilisate added to 100 ml bidest. water) under stirring the finished solution became quickly clear and had a slightly whitish appearance.

[0183] The bitter taste of azithromycin—which often causes a compliance problem, especially with children—could be covered by this solubilisate.

Example 2: Solubilization of Aciclovir

[0184] Aciclovir is an antiviral pharmaceutical agent. It is frequently used in the treatment of Herpes simplex infections, shingles and chickenpox. Aciclovir belongs to BCS Class 4 (low solubility—low permeability) pharmaceuticals.

[0185] Ca. 10 ml of a solubilisate of azithromycin were generated by the following procedure: 200 mg aciclovir (Sigma-Aldrich, Darmstadt, Germany) were provided. 5.7 g dimyristoyl phosphatidylcholine (DMPC; Lipoid GmbH, Ludwigshafen, Germany), 3.2 ml MCT oil (Azelis, Moers, Germany), 300 mg of a mixture of 1-lysophosphatidylcholine and 2-lysophosphatidycholine (weight ratio: 1:1; Lipoid GmbH, Ludwigshafen, Germany), 250 μl ethanol, 120 μl oleic acid, 190 mg glyceryl stearate, 15 μl glyceryl oleate and 5 mg tocopherol were added under stirring for 5 min at room temperature (20±5° C.) and atmospheric pressure. Then the composition was cautiously heated under continued stirring, with an approximate temperature increment of 1° C./min. After ca. 45 min (ca. 65° C.) the composition started to become a clear solution. This solubilization process lasted for ca. 5 min more. Thus a solubilisate according to the invention was obtained after ca. 50 min at ca. 70° C. Then the heating and the stirring was stopped and the resulting solubilisate was allowed to cool down to room temperature. The solubilisate stayed clear and stable over min. 3 weeks.

[0186] Upon being diluted into an aqueous finished solution (2 ml solubilisate added to 100 ml bidest. water) under stirring the finished solution became quickly clear and had a slightly whitish appearance.

[0187] The taste of aciclovir—which patients often describe as unpleasant, sometimes also as metallic—could be covered by this solubilisate.

Example 3: Solubilization of Hydrochlorothiazide

[0188] Hydrochlorothiazide is a diuretic pharmaceutical agent. It is frequently used in the treatment of high blood pressure, swelling due to fluid build-up, diabetes insipidus, renal tubular acidosis and in the prophylaxis of persons with an elevated risk of kidneys stones. Hydrochlorothiazide belongs to BCS Class 4 (low solubility—low permeability) pharmaceuticals.

[0189] Ca. 10 ml of a solubilisate of hydrochlorothiazide were generated by the following procedure: 200 mg hydrochlorothiazide (Sigma-Aldrich, Darmstadt, Germany) were provided. 5 g of non-hydrogenated soy bean PC and POPC (weight ratio: 1:1; Lipoid GmbH, Ludwigshafen, Germany), 4 ml MCT oil (Azelis, Moers, Germany), 260 mg L-alpha-lysophosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany), 220 μl ethanol, 175 μl oleic acid, 190 mg glyceryl stearate and 20 μl glyceryl oleate were added under stirring for 5 min at room temperature (20±5° C.) and atmospheric pressure. Then the composition was cautiously heated under continued stirring, with an approximate temperature increment of 1° C./min. After ca. 38 min (ca. 58° C.) the composition started to become a clear solution. This solubilization process lasted for ca. 7 min more. Thus a solubilisate according to the invention was obtained after ca. 45 min at ca. 65° C. Then the heating and the stirring was stopped and the resulting solubilisate was allowed to cool down to room temperature. The solubilisate stayed clear and stable over min. 4 weeks.

[0190] Upon being diluted into an aqueous finished solution (2 ml solubilisate added to 100 ml bidest. water) under stirring the finished solution became quickly clear and had a slightly whitish appearance.

[0191] The taste of hydrochlorothiazide—which patients often describe as metallic—could be covered by this solubilisate.

Example 4: Solubilization of Coenzyme Q.SUB.10

[0192] Coenzyme Q.sub.10 (synonyms: ubiquinone, ubidecarone, coenzyme Q, CoQ.sub.10) is a ubiquitous coenzyme in most animals. Three redox states of coenzyme Q.sub.10 have been described. The molecule acts as a two electron carrier and a one electron carrier, corresponding to its role in the electron transport chain and as a radical scavenger. Coenzyme Q.sub.10 is hardly soluble in an aqueous environment and poorly absorbed in the body. However, it is a broadly marketed dietary supplement.

[0193] Ca. 10 ml of a solubilisate of coenzyme Q.sub.10 were generated by the following procedure: 400 mg coenzyme Q.sub.10 (Merck, Darmstadt, Germany) were provided. 2.6 g non-hydrogenated soy bean phosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany), 6.3 ml MCT oil (Azelis, Moers, Germany), 280 mg 2-lysophosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany), 180 μl ethanol, 90 μl oleic acid, 140 mg glyceryl stearate, 20 μl glyceryl oleate and 5 mg tocopherol were added under stirring for 5 min at room temperature (20±5° C.) and atmospheric pressure. Then the composition was cautiously heated under continued stirring, with an approximate temperature increment of 0.5° C./min. After ca. 36 min (ca. 38° C.) the composition started to become a clear solution. This solubilization process lasted for ca. 12 min more. Thus a solubilisate according to the invention was obtained after ca. 48 min at ca. 44° C. Then the heating and the stirring was stopped and the resulting solubilisate was allowed to cool down to room temperature. The color of the solubilisate was intense orange. The solubilisate stayed clear and stable over min. 2 months.

[0194] Upon being diluted into an aqueous finished solution (2 ml solubilisate added to 100 ml bidest. water) under stirring the finished solution became quickly clear and had a milky white yellowish appearance.

Example 5: Solubilization of Piperine

[0195] Piperine (IUPAC name: 1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]piperidine) is the main alkaloid from Piper negrum (black pepper) and usually won by alcoholic extraction. It is a colorless to yellow solid at room temperature and poorly water-soluble. As many spicy substances piperine stimulates metabolism and gastrointestinal secretion, and it displays antimicrobial actions. Furthermore, it is a bioavailability enhancer. It was found to inhibit human CYP3A4 and P-glycoprotein, two enzymes involved in first-pass metabolism of xenobiotics. Thus, it can be used as a dietary supplement and/or as a bioavailability enhancer of other substances (mainly other dietary supplements).

[0196] Ca. 10 ml of a solubilisate of piperine were generated by the following procedure: 200 mg piperine extract (Sabinsa, Langen, Germany) were provided. 3.1 g 1,2-dioleyl-SN-glycero-3-phosphocholine (DOPC; Lipoid GmbH, Ludwigshafen, Germany), 5.8 ml MCT oil (Azelis, Moers, Germany), 300 mg 1-lysophosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany), 270 μl ethanol, 110 μl oleic acid, 170 mg glyceryl stearate, 15 μl glyceryl oleate and 8 mg tocopherol were added under stirring for 5 min at room temperature (20 t 5° C.) and atmospheric pressure. Then the composition was cautiously heated under continued stirring, with an approximate temperature increment of 1.5° C./min. After ca. 27 min (ca. 60° C.) the composition started to become a clear solution. This solubilization process lasted for ca. 16 min more. Thus a solubilisate according to the invention was obtained after ca. 43 min at ca. 85° C. Then the heating and the stirring was stopped and the resulting solubilisate was allowed to cool down to room temperature. The color of the solubilisate was intense yellow. The solubilisate stayed clear and stable over min. 12 months.

[0197] Upon being diluted into an aqueous finished solution (2 ml solubilisate added to 100 ml bidest. water) under stirring the finished solution became quickly clear and had a pale white appearance.

[0198] The characteristic poignant taste (more accurately, odor) of piperine could be covered by this solubilisate.

Example 6: Solubilization of Green Tea Extract

[0199] Green tea extract is produced from green tea leaves (Camellia sinensis). The main components are green tea catechins, such as epigallocatechin-3-gallate (EGCG), epicatechin (EC), epicatechin-3-gallate (ECg), epigallocatechin (EGC), catechin, and gallocatechin (GC), with EGCG being the most abundant of them in green tea extract. Green tea extract is often used as a dietary supplement, aiming at healthy effects attributed to catechins. They include above all antioxidant, anticarcinogenic, anti-inflammatory and anti-radiation actions. However, catechins, in particular EGCG, show a poor bioavailability and the solubility in water is rather limited.

[0200] Ca. 10 ml of a solubilisate of green tea extract were generated by the following procedure: 300 mg green tea extract (Sabinsa, Langen, Germany) were provided. 3 g phosphatidylcholine (PC and DMPC, weight ratio 1:1; Lipoid GmbH, Ludwigshafen, Germany), 5.9 ml MCT oil (Azelis, Moers, Germany), 280 mg 2-lysophosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany), 250 μl ethanol, 80 μl oleic acid, 160 mg glyceryl stearate, 20 μl glyceryl oleate and 14 mg tocopherol were added under stirring for 5 min at room temperature (20 t 5° C.) and atmospheric pressure. Then the composition was cautiously heated under continued stirring, with an approximate temperature increment of 2.5° C./min. After ca. 33 min (ca. 102° C.) the composition started to become a clear solution. This solubilization process lasted for ca. 4 min more. Thus a solubilisate according to the invention was obtained after ca. 36 min at ca. 110° C. Then the heating and the stirring was stopped and the resulting solubilisate was allowed to cool down to room temperature. The color of the solubilisate was dark brownish. The solubilisate stayed clear and stable over min. 16 months.

[0201] Upon being diluted into an aqueous finished solution (2 ml solubilisate added to 100 ml bidest. water) under stirring the finished solution became quickly clear and had a pale white brownish appearance.

[0202] The grassy (herbal) taste of diluted green tea extract could be covered by this solubilisate. This also holds true for the sometimes bitter taste of green tea, depending on the blend, which renders green tea unpopular for some people.